Aytu BioScience Revenue and Competitors

Denver, CO USA

Location

$32M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Aytu BioScience's estimated annual revenue is currently $27.5M per year.(i)
  • Aytu BioScience's estimated revenue per employee is $201,000
  • Aytu BioScience's total funding is $32M.

Employee Data

  • Aytu BioScience has 137 Employees.(i)
  • Aytu BioScience grew their employee count by -4% last year.

Aytu BioScience's People

NameTitleEmail/Phone
1
VP OperationsReveal Email/Phone
2
EVP & Corporate OperationsReveal Email/Phone
3
VP Regulatory Affairs and Quality AssuranceReveal Email/Phone
4
VP, Trade & Market AccessReveal Email/Phone
5
DirectorReveal Email/Phone
6
Sr. Director, Organizational Insights and AnalyticsReveal Email/Phone
7
Director, MarketingReveal Email/Phone
8
Chief Commercial OfficerReveal Email/Phone
9
Director DiagnosticsReveal Email/Phone
10
Executive Assistant/ Office ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M250%N/AN/A
#2
$10.3M516%N/AN/A
#3
$4.4M22-8%N/AN/A
#4
$195M1220%$121.4MN/A
#5
$4.8M24-20%N/AN/A
#6
$6.8M34-19%N/AN/A
#7
$4.8M240%N/AN/A
#8
$4M40-11%$138MN/A
#9
$4.8M24-14%N/AN/A
#10
$69.5M346-6%N/AN/A
Add Company

What Is Aytu BioScience?

Aytu BioScience, Inc. is a specialty healthcare company focused on developing treatments for urological and related conditions. The Company is currently completing Phase 3 clinical development for its lead therapeutic candidate Zertane™, an orally disintegrating tablet (ODT) formulated specifically for the on-demand treatment of premature ejaculation (PE). The Company's therapeutic pipeline is supported in part by its first-in-class RedoxSYS® System, which provides the only complete assessment of patients' redox status and enables identification of a broad variety of disorders where redox is implicated. Clinical studies are underway utilizing the RedoxSYS system in male fertility. The Company also recently acquired and is commercializing FDA-approved ProstaScint® (capromab pendetide), a radio-labeled monoclonal antibody, that targets Prostate Specific Membrane Antigen (PSMA), a protein uniquely expressed by prostate tissue. The Company's strategy is to develop its core therapeutic and diagnostic assets while building an innovative pipeline of established marketed products and late-stage development assets.

keywords:N/A

$32M

Total Funding

137

Number of Employees

$27.5M

Revenue (est)

-4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Aytu BioScience News

2022-04-17 - Aytu BioPharma (NASDAQ:AYTU) Rating Lowered to Hold at Zacks ... Defense World

Aytu BioPharma (NASDAQ:AYTU) Rating Lowered to Hold at Zacks ... Defense World

2022-04-17 - Axsome and Aytu's Positive Day with the FDA BioSpace

Axsome and Aytu's Positive Day with the FDA BioSpace

2022-04-17 - Aytu BioScience (AYTU) Granted FDA Fast Track Designation for ... StreetInsider

Aytu BioScience (AYTU) Granted FDA Fast Track Designation for ... StreetInsider

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$20.7M1388%N/A
#2
$13.9M1390%N/A
#3
$40.3M13951%N/A
#4
$22.9M13916%N/A
#5
$33.9M140-13%N/A